HDAC inhibitors are potential anticancer drugs because of their ability to induce tumor cell differentiation, cell cycle arrest, and cell death, attenuate angiogenesis, reverse transformed cell morphology, and regulate immune response (172). This evidence concerns the gene HDAC9 and neoplasm.